ALXO - ALX Oncology under pressure as director sells shares worth $4.7M

ALX Oncology (ALXO -25.1%) shares have plunged after the company disclosed a sale of shares by director Jason Lettmann. Lettmann sold 145,637 shares of the company's common stock at $30.12 - $33.92 in a series of transactions, worth ~$4.7M. Form 4 A look at ALXO's ownership composition: Learn why ALXO is at high risk of performing badly The immuno-oncology firm reported its Q3 results last month, missing on EPS estimates. Nevertheless, ALX Oncology at their current stock price is much more attractive, says SA contributor Ian Henrich says in a recent bullish analysis on the stock

For further details see:

ALX Oncology under pressure as director sells shares worth $4.7M